Jul 2026· Cardiology in the Young· pp.
1-12
· 0 citations· 36 references
Medicine
TL;DR
As the first genetic study of hypertrophic cardiomyopathy in an Egyptian population, this work expands the global mutational spectrum, demonstrates the utility of genetic testing for risk stratification and personalised management, and underscores the need to diversify genomic datasets for equitable precision medicine.
Abstract
Background
AND
Objectives
Hypertrophic cardiomyopathy is a life-threatening disease with limited studies in Middle Eastern populations. This pilot study (n = 8) aimed to identify rare genetic variants to enable future presymptomatic diagnosis and primary prevention. While the sample size precludes establishing population-level prevalence, our findings provide a springboard for generating testable hypotheses for future multicenter trials.
Methods
Whole-exome sequencing was performed on eight unrelated Egyptian patients. We prioritised variants using stringent criteria: allele frequency < 0.01 in gnomAD, combined annotation dependent depletion (CADD) score > 10, and focused analysis of 29 genes with definitive or moderate evidence for hypertrophic cardiomyopathy causation according to Clinical Genome Resource (ClinGen). Variants were ACMG/AMP-classified and correlated with detailed clinical phenotypes.
Results
We identified 21 rare variants across 10 hypertrophic cardiomyopathy-associated genes. Core sarcomeric genes accounted for seven variants: MYBPC3 (n = 2; one likely pathogenic, p.Gly1206Asp), MYH7 (n = 2; one pathogenic, p.Phe252Ser), and TNNT2 (n = 3; all variants of uncertain significance). Additionally, likely pathogenic variants were found in PLN (p.Arg25Cys) and KLHL24 (p.Arg103*). Patients with pathogenic or likely pathogenic sarcomeric variants exhibited severe phenotypes, including septal thickness up to 30 mm, left ventricular outflow tract gradients up to 60 mmHg, and a high arrhythmic burden, influencing decisions like implantable cardioverter-defibrillator implantation and myectomy. Notably, all three TNNT2 carriers manifested atrial fibrillation or non-sustained ventricular tachycardia, reinforcing its arrhythmic risk. Four novel or likely pathogenic variants were submitted to ClinVar.
Conclusion
As the first genetic study of hypertrophic cardiomyopathy in an Egyptian population, this work expands the global mutational spectrum, demonstrates the utility of genetic testing for risk stratification and personalised management, and underscores the need to diversify genomic datasets for equitable precision medicine.
Background: Pediatric dilated cardiomyopathy (DCM) is a genetically heterogeneous disorder with limited population-specific genetic data in Middle Eastern cohorts. Methods: Twenty-three pediatric DCM patients from a predominantly Kurdish–Arab consanguineous population underwent comprehensive clinical evaluation and targeted next-generation sequencing (NGS) using a 152-gene cardiomyopathy panel. Variants were classified according to ACMG/AMP guidelines. Results: Targeted NGS identified 163 rare variants; 24 (14.7%) were pathogenic/likely pathogenic (P/LP), 76 (46.6%) were variants of uncertain significance (VUS), and 63 (38.7%) were benign/likely benign. The overall diagnostic yield was 78.3% (18/23). The SCN5A c.1921delC (p.Gln641ArgfsTer3) frameshift variant was the most frequently detected P/LP variant, present in 69.6% of patients. No significant genotype–phenotype correlations were observed for SCN5A c.1921delC regarding age of onset, left ventricular ejection fraction, or valvular/structural abnormalities. Parental consanguinity was high (66.7%), and disease onset occurred early (mean 2.0 ± 3.27 years). Conclusions: This is the first genetic evaluation of a pediatric cohort with DCM from a mixed Kurdish–Arab population. A high diagnostic yield of DCM was found, particularly in consanguineous families, including an SCN5A recurrent variant. The study highlights the utility of targeted NGS in a consanguineous population. Further related studies are required in this region.
Hawre Mohammed Fatah, Dlnya A. Mohammed, A. Salih· Cardiogenetics· 0 citations
Parkinson’s disease (PD), a complex neurodegenerative disorder, is increasingly prevalent, with a strong genetic component. While environmental factors contribute, the exact cause remains elusive. Understanding PD’s genetic basis is vital for advancing research and treatment. This study seeks to investigate the genetic diversity of Parkinson’s disease in the Algerian population using whole exome sequencing (WES), with the goal of identifying rare variants across genes potentially associated with the disease. Whole exome sequencing (WES) was performed on a cohort of 19 Algerian patients with clinically confirmed Parkinson’s disease, including 8 patients with a positive family history. Variant annotation and functional effect prediction were performed using SnpEff, in conjunction with multiple reference genomic databases. Variant calling results were stored in Variant Call Format (VCF). Variants were classified according to their minor allele frequency (MAF): rare variants were defined as those with a MAF between 0.1% and 1%, while novel variants were defined as those with a MAF ≤ 0.1% or absent from all queried reference databases. Whole exome sequencing analysis identified 73 variants distributed across 22 genes in 19 Algerian patients with Parkinson’s disease. Following prioritization, nine variants were detected across six candidate genes (DDOST, AUP1, SNORD66, TRPM7, ORC6, and GLUD2), whose association with Parkinson’s disease had not been previously reported in North African populations. These genes are involved in several cellular functions, including protein homeostasis, DNA repair, cellular metabolism, and oxidative stress response. Among them, GLUD2 emerges as a particularly compelling candidate requiring functional validation for future investigations. This preliminary study highlights the genetic diversity of Parkinson’s disease in the Algerian population and underscores the value of whole exome sequencing for the identification of rare variants in underrepresented populations. The findings suggest potential novel research avenues that may contribute to expanding knowledge of the genetic architecture of the disease. Replication studies and functional validation will be required to confirm the biological and clinical relevance of the identified variants.
F. Sellali, Amina Belhadj, Noria Bouras et al.· Egyptian Journal of Medical...· 0 citations
The results suggest that single‐gene causes are rare in adults with TLE, consistent with previous reports indicating a low diagnostic yield of presurgical genetic testing and further support a predominantly polygenic architecture of TLE.
Antonia P. Pirker, Margot Ernst, Matias Wagner et al.· Epilepsia Open· 0 citations
Background/Objectives: Dilated cardiomyopathy is a heterogeneous disorder with a substantial genetic contribution from a variety of pathogenic variants. Hereditary isolated DCM is often caused by variants in genes encoding sarcomere proteins, as well as proteins involved in desmosomes or other cardiac cell functions. Identifying genetic causes improves our understanding of DCM pathophysiology, facilitates prognostic assessment, and enables more personalized disease management. Methods: We retrospectively analyzed genetic data from adult patients with a clinical diagnosis of isolated DCM evaluated at a Lithuanian tertiary university hospital between 2019 and 2024. All patients were tested with a next-generation sequencing cardiovascular gene panel. Results: We gathered 169 patients and initially reached a 16.0% (n = 27) genetic testing diagnostic yield. We performed all genetic variant reanalyses with the most current classification guidelines, and we found an additional eight positive cases. Our final diagnostic yield was 20.7% (n = 35). TTN was the most frequently affected gene (n = 30), whereas variants in BAG3 (n = 2), DSP (n = 1), LMNA (n = 1), and FLNC (n = 1) were rare. In total, 15 variants were novel—not described in the literature or databases. We did not observe significant clinical differences between patients with pathogenic variants and those without pathogenic variants. We expected a different clinical course with variants in genes like BAG3 or LMNA, but there were only a few cases. Conclusions: Genetic testing remains an important tool for confirming complex DCM cases and allows earlier disease management for relatives at risk.
M. Šukys, Eglė Ereminienė, Kristina Aleknavičienė et al.· Diagnostics· 0 citations
The identification of novel variants enhances molecular understanding and facilitates more precise genotype-phenotype correlations, reinforcing the value of comprehensive genomic diagnostics in epilepsy management and demonstrating the clinical utility of gene panels and WES in complex phenotypes.
Renata Szalai, Á. Till, Krisztina Galimurka et al.· Human Genetics· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.